34
Participants
Start Date
June 29, 2011
Primary Completion Date
November 4, 2014
Study Completion Date
August 27, 2015
Anti-tumor necrosis factor alpha monoclonal antibody
The dose of adalimumab will be 40 mg for children age 13 and over and for children younger than 13 adalimumab 24 mg per m2 BSA (up to a maximum total body dose of 40 mg).
placebo
Patients will receive 4 injections of placebo on D0, D14, D28, and D42 with assessment of the primary endpoint at M2
Hospital of necker Enfants malades, Paris
Collaborators (1)
Abbott
INDUSTRY
URC-CIC Paris Descartes Necker Cochin
OTHER
Assistance Publique - Hôpitaux de Paris
OTHER